Get the Stockscreener App
762.93
0.37%
2.80
After Hours:
761.00
-1.93
-0.25%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $762.93, with a volume of 3.46M.
It is up +0.37% in the last 24 hours and up +9.29% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$760.13
Open:
$761.38
24h Volume:
3.46M
Relative Volume:
0.80
Market Cap:
$722.08B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
49.86
EPS:
15.3
Net Cash Flow:
$-50.20M
1W Performance:
+0.88%
1M Performance:
+9.29%
6M Performance:
-7.24%
1Y Performance:
-15.70%
1-Day Range:
$759.01
$772.53
1-Week Range:
$742.11
$776.96
52-Week Range:
$623.78
$939.86
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
762.93 | 681.42B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.16 | 426.76B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
221.99 | 390.07B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.29 | 237.08B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
NVO
Novo Nordisk Adr
|
61.85 | 258.61B | 45.44B | 16.18B | 9.21B | 3.634 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly’s (LLY) AI Chief Joins the Board of GeneDx - TipRanks
Eli Lilly expands globally with a focus on obesity drugs - MarketScreener
Lilly to build $5B cancer drug facility in Virginia - Manufacturing Dive
Berenberg Cools On Eli Lilly As Obesity Drug Competition Heats Up - Finimize
Eli Lilly Stock Outlook: Fast-Track Oral GLP-1 Review Meets Long-Term Catalysts - Investing.com
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything - MarketBeat
After Mounjaro Jab, Eli Lilly plans weight loss pill launch in India - The Economic Times
Eli Lilly AI chief Thomas Fuchs joins GeneDx board of directors - Investing.com Canada
Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents - MSN
Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Obesity and Diabetes Treatment - TipRanks
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Benzinga
Eli Lilly to Build $5B US Manufacturing Plant - Powder & Bulk Solids
Eli Lilly stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com UK
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says - Barron's
Eli Lilly To Build $5B Plant In Virginia - InkFreeNews.com
Eli Lilly (LLY) Advances Tirzepatide for Pediatric Diabetes - GuruFocus
Eli Lilly Announces Plans for $5B Pharmaceutical Manufacturing Facility Near Richmond, Virginia - REBusinessOnline
Eli Lilly posts late-stage trial win for Mounjaro in children and adolescents with diabetes (LLY:NYSE) - Seeking Alpha
Eli Lilly to build $5 billion manufacturing facility in Virginia - Robotics & Automation News
Eli Lilly and Company $LLY Shares Acquired by Ayrshire Capital Management LLC - MarketBeat
Eli Lilly's UK turnover almost doubles after Mounjaro sale - business-live.co.uk
Procyon Advisors LLC Reduces Holdings in Eli Lilly and Company $LLY - MarketBeat
How Eli Lilly And Company (LLY) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Eli Lilly’s Strong Oral Weight-Loss Drug Data Solidifies Its Leading Position in the GLP-1 Market - NAI500
Sen. John Boozman Buys Eli Lilly and Company (NYSE:LLY) Shares - MarketBeat
Drugmaker Eli Lilly to build $5 billion facility in Virginia - The Virginian-Pilot
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Moun - GuruFocus
Lilly Seeks Approval of Mounjaro for Diabetic Kids After Study Shows Benefit - Bloomberg.com
Is Eli Lilly a Bargain After $350B U.S. Manufacturing Investment Announcement? - simplywall.st
Eli Lilly to Invest $5B in Virginia Plant for Cancer Drugs - uk.finance.yahoo.com
Eli Lilly’s Orforglipron Shows Superior Results in Diabetes Trial - TipRanks
Eli Lilly (LLY) to File for Weight-Loss Pill Approval in Multiple Markets - TipRanks
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms (NYSE:LLY) - Seeking Alpha
Eli Lilly Plans $5B Va. Factory, With More US Plants To Follow - Law360
Eli Lilly to invest $5B on new Virginia manufacturing facility - WTOP
Lilly gets a boost from new weight-loss pill data as it weighs speedier approval in US - Reuters
Regeneron, Elf Beauty, Eli Lilly - TradingView
Eli Lilly’s oral GLP-1 shows greater efficacy than semaglutide, eyes approval by year-end - Times of India
EXCLUSIVE: White House touts Eli Lilly's "new multi-billion dollar drug manufacturing plant" in Virginia - Washington Reporter
Eli Lilly (LLY) Faces FDA Scrutiny over Drug Promotion Practices - GuruFocus
Lilly’s GLP-1 Pill Beats Older Novo Diabetes Drug in Head-to-Head Trial - Bloomberg.com
Eli Lilly Rolls Out Its GLP-1 Strategy Worldwide - The Business of Fashion
Eli Lilly gets a boost from new pill data; execs say US fast track not a sure thing - Reuters
Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD - BioPharma Dive
$5B Eli Lilly facility to be built in Virginia - MSN
Lilly's GLP-1 Pill Outperforms Older Novo Drug - MarketScreener
Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss? - AOL.com
Eli Lilly (LLY) Reports Superior Diabetes Drug Results - GuruFocus
Eli Lilly reports ‘positive’ results from ACHIEVE-3 Phase 3 trial - TipRanks
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.72%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):